Savara to Present at H.C. Wainwright Global Investment Conference

Rhea-AI Summary

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company specializing in rare respiratory diseases, will present at the H.C. Wainwright Global Investment Conference on May 24, 2022, at 4:00 pm ET. The presentation will be broadcast live and available for 90 days on Savara's website.

Savara's leading program, molgramostim nebulizer solution, is in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP) and is delivered via the investigational eFlow® Nebulizer System.

AUSTIN, Texas--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the H.C. Wainwright Global Investment Conference on May 24, 2022 at 4:00 pm ET. A live webcast of the presentation will be available on Savara’s website at www.savarapharma.com/investors/events-presentations/ and will be archived for 90 days.

About Savara

Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com. (Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).

View source version on businesswire.com: https://www.businesswire.com/news/home/20220517005163/en/

Savara Inc. IR & PR

Anne Erickson

Senior Vice President, Chief of Staff

anne.erickson@savarapharma.com

(512) 851-1366

Source: Savara Inc.

FAQ

When will Savara Inc. present at the H.C. Wainwright Global Investment Conference?

Savara Inc. will present on May 24, 2022, at 4:00 pm ET.

Is there a webcast available for Savara Inc.'s conference presentation?

Yes, a live webcast will be available on Savara's website and will be archived for 90 days.

What is the focus of Savara Inc.'s lead program, molgramostim?

Molgramostim is in Phase 3 development for treating autoimmune pulmonary alveolar proteinosis (aPAP).

What device is used to deliver Savara's molgramostim treatment?

The treatment is delivered via an investigational eFlow® Nebulizer System.

Which stock symbol represents Savara Inc. on NASDAQ?

Savara Inc. is represented by the stock symbol SVRA.